Barringer Technologies Develops a Bacteria Detection Application for Its IONSCAN Trace Detector
BUSINESS WIRE - March 14, 2000 07:30
WARREN, N.J., Mar 14, 2000 (BUSINESS WIRE) --
- Preliminary Field Test Results to be Presented at Pittsburgh Conference on March 15, 2000 -
Barringer Technologies Inc. (NASDAQ: BARR), the world's leading developer, manufacturer and marketer of drug and explosive trace detection equipment, announced today that it has developed a bacteria detection application for its IONSCAN (R) detector working collaboratively with the University of Connecticut. A presentation of this capability, and preliminary field test results, will be presented on March 15, 2000 to the Pittsburgh Conference, the world's largest analytical instrumentation conference.
Mr. J. Richard Jadamec, Co-Director Coastal Environmental Laboratories at the University of Connecticut, commented, "The detection algorithms we have developed provide specific detection and identification of a variety of bacterial species, such as Listeria, E. coli, and Serratia marcescens which are typically found in pathogenic contaminants in food and water. We are now field testing the IONSCAN's (R) Listeria detection capabilities, running side by side tests with other commercial techniques. Results to date have been extraordinary in terms of identifying and differentiating the pathogenic Listeria monocytogenes from other species of Listeria. Once fully developed, the IONSCAN (R) is expected to offer shorter response times than existing techniques and much lower costs per sample for a wide variety of bacterial detection applications."
Mr. Kenneth Wood, President and Chief Operating Officer of Barringer Technologies, further noted, "Our joint effort with the University of Connecticut began last year pursuant to our strategic growth plan to develop new market opportunities for our core technology in the life sciences field. We're very excited about the results obtained to date and the potential of using the IONSCAN (R) to provide quicker and significantly less expensive detection and identification capability for a number of bacterial applications. We believe that there are significant market opportunities in food, clinical, and environmental microbiological testing laboratories for the detection and identification of bacterial pathogens. Further, we expect to explore the possibility of extending this capability to the detection of biological warfare agents, which is one of the next major areas of focus for military and civil defense agencies around the world."
Mr. Wood continued "We are presently assessing various marketing and sales distribution options including scientific product distributors as well as in-house sales and marketing in anticipation of commercializing this capability late in the second half of 2000."
Headquartered in Warren, New Jersey, Barringer Technologies Inc. is principally engaged in the developing, manufacturing and marketing of high technology products for drug and explosive detection and other security and industrial applications. The SABRE 2000(R) and the IONSCAN (R) are the Company's proprietary trace particle drug and explosive detection units.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. When used in this press release, the words "estimate," "project," "believe," "anticipate, "intend," "expect", "plan," "predict," "may," "should," "will," the negative thereof and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views of the Company with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Factors that could cause actual results to differ materially from the Company's expectations include, but are not limited to, the following: delays and difficulties in completing the development of the new applications described above and unexpected costs that may be incurred in connection therewith, the utility of any new applications that are ultimately developed, the ability of the Company to successfully market such new applications and market acceptance of such new applications. Other factors may be described from time to time in the Company's public filings with the Securities and Exchange Commission, news releases and other communications. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to release publicly any revisions to these forward- looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Distributed via COMTEX.
Copyright (C) 2000 Business Wire. All rights reserved.
-0-
CONTACT: Barringer Technologies Inc. Stanley Binder, Chairman and CEO Richard S. Rosenfeld, CFO Barringer Technologies Inc. (908) 222-9100 -or- Cheryl Schneider/John Blackwell Press: David Nugent/Ellen Paz Morgen-Walke Associates, Inc. (212) 850-5600
KEYWORD: NEW JERSEY
INDUSTRY KEYWORD: BIOTECHNOLOGY
COMPUTERS/ELECTRONICS
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
News provided by COMTEX |
